Preferences of women with epithelial ovarian cancer for aspects of genetic testing.

Published online

Journal Article

Background: Although genetic testing is recommended for women with epithelial ovarian cancer (EOC), little is known about patient preferences for various testing options. We measured relative preferences for attributes of testing in women with EOC referred for genetic counseling. Methods: Subjects were recruited to participate in a discrete-choice-experiment survey to elicit preferences for attributes of genetic testing: out-of-pocket cost ($0, $100, $250, or $1000), probability of a deleterious mutation (60, 80%, or 88%), probability of a variant of uncertain significance (VUS) result (5, 20%, or 40%), sample requirements (blood or saliva), and turn-around time (1, 2 or 4 weeks). Subjects viewed educational videos followed by a series of choices between pairs of constructed genetic tests with varying attribute levels. Random-parameters logit was used to estimate preference weights for attribute levels. Relative importance weights and money-equivalent values were calculated. Results: Ninety-four patients were enrolled; 68 (76.4%) presented for genetic counseling. Test cost was the most important attribute to subjects (importance weight = 41 out of 100) followed by probability to detect deleterious mutations (36) and probability of a VUS result (20). Sample requirements and turnaround time did not drive test choices. Subjects were willing to pay an additional $155 and $70 for incremental 5% improvements in the probability to detect deleterious mutations and probability of a VUS result. At genetics consultation, 55/68 (80.9%) subjects chose multigene testing. Conclusions: Low out-of-pocket cost, high probability of detecting deleterious mutations and high probability of a VUS result are preferred by patients with EOC considering genetic testing.

Full Text

Duke Authors

Cited Authors

  • Davidson, BA; Ehrisman, J; Reed, SD; Yang, J-C; Buchanan, A; Havrilesky, LJ

Published Date

  • 2019

Published In

Volume / Issue

  • 6 /

Start / End Page

  • 1 -

PubMed ID

  • 30693090

Pubmed Central ID

  • 30693090

Electronic International Standard Serial Number (EISSN)

  • 2053-6844

Digital Object Identifier (DOI)

  • 10.1186/s40661-019-0066-8


  • eng

Conference Location

  • England